問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Division of Pediatrics

Division of Pediatrics

MacKay Memorial Hospital

Division of Pediatrics

更新時間：2023-09-19

邱南昌Chiu, Nan-Chang
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

  • asumiwang@gmail.com

Recruiting Trial

11Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱南昌

List

35Cases

2014-10-01 - 2016-12-31

Phase III

Safety and immunogenicity study of GSK Biologicals’ MMR vaccine (209762) comparing immunogenicity and safety to Merck & Co., Inc.’s MMR vaccine, in healthy children 12 to 15 months of age.

  • Condition/Disease

    Measles, mumps and rubella

  • Test Drug

    Measles, mumps and rubella (MMR) vaccine live

Participate Sites
8Sites

Terminated8Sites

2014-07-01 - 2017-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2019-03-01 - 2021-10-25

Phase III

A Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled, Multi-region Study to Evaluate the Efficacy, Safety, and Immunogenicity of Inactivated EV71 Vaccine Produced in Vero Cells With Adjuvant in Infants and Children

  • Condition/Disease

    Enterovirus 71 Infection

  • Test Drug

    EV71 Vaccine

Participate Sites
5Sites

Terminated5Sites

邱政洵
Linkou Chang Gung Medical Foundation

Division of Pediatrics

2021-06-21 - 2022-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-12-01 - 2022-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator Controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants (PNEU -LINK)

  • Condition/Disease

    Pneumococcal Infections

  • Test Drug

    15-Valent Pneumococcal Conjugate Vaccine (V114)

Participate Sites
4Sites

Terminated4Sites

邱政洵
Linkou Chang Gung Medical Foundation

Division of Pediatrics

2021-04-09 - 2024-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-12-01 - 2025-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-10-11 - 2024-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2010-06-01 - 2011-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2019-09-20 - 2022-12-31

Phase II

A Phase 2A, 2-Part Open-Label, Non-Randomized, Multicenter, Single and Multiple Dose Trial to Evaluate Pharmacokinetics, Safety and Tolerability of Ceftazidime and Avibactam in Neonates and Infants From Birth to Less Than 3 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment

  • Condition/Disease

    Gram-negative Bacterial Infection

  • Test Drug

    ceftazidime-avibactam

Participate Sites
7Sites

Recruiting7Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB